09 Jul 2014 Posted in ABPI statement By Stephen Whitehead
“Animal research plays a key role in bio-medical research, helping us to better understand and improve the treatment of diseases in humans and animals. The number of animals used in the procedures carried out should be seen in the context that such research is contributing to the many of the medical advances we now take for granted in areas such as diabetes, asthma and HIV. It is also critical to the development of the next generation of medicines and accounts for the saving of millions of lives around the world. It is also important to note that over half of all procedures relate to the breeding of genetically modified animals1, even where the animals experience no further research procedures.
“The biopharmaceutical industry is fully committed to the 3Rs2, and I am pleased to see that the dynamic collaboration between the ABPI and the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) is entering its tenth year. Through this collaboration we will continue to sustain and further cultivate the innovative work and valuable outputs that have been produced so far."
1Genetically modified animals can be very useful for studying diseases which are caused, or partially caused, by faults in the genetic code. Many diseases are now thought to have a genetic component, including cancer, diabetes and dementia, and research on genetically modified animals will be crucial in developing new medicines for these diseases.
2The 3Rs - Replacement of animals with non-animal methods or less sentient species as appropriate, Reduction of the numbers of animals used and Refinement of procedures to minimise harm to the animals involved.
Pharmaceutical research and development makes a valuable contribution most importantly to health, but also to the UK economy. Our members have been responsible for the development of 90% of the medicines in the world and there are many diseases which, without vital research using animals, would not be managed the way they are today.
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811